CD8A and neoplasm: The engineering platforms provide an opportunity to produce cancer-specific CD4+ T cells capable of recognising tumour cells via MHC class-I-restricted TCRs and contribute to protection by directly killing cancer cells and/or by improving the effector function and memory formation of CD8+ T cells.